Alkermes schizophrenia treatment meets main goals in late-stage study [Reuters]
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: Reuters
Alkermes schizophrenia treatment meets main goals in late-stage study | Reuters 1 Min Read (Reuters) - Alkermes Plc said on Thursday its treatment for schizophrenia met the main goals in a late-stage study and demonstrated a favorable weight profile, compared with antipsychotic agent olanzapine. The company said it plans to submit the marketing application to the U.S. Food and Drug Administration in mid-2019. Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D'Silva All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. Alkermes schizophrenia treatment meets main goals in late-stage study (Reuters) - Alkermes Plc said on Thursday its treatment for schizophrenia met the main goals in a late-stage study and demonstrated a favorable weight profile, compared with antipsychotic agent olanzapine. The company said it plans to submit the marketing application to the U.S. Food and Drug Administr
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
- Alkermes plc Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Alkermes plc Reports First Quarter 2024 Financial ResultsPR Newswire
- Alkermes plc Reports First Quarter 2024 Financial ResultsPR Newswire
- Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 [Yahoo! Finance]Yahoo! Finance
ALKS
Earnings
- 5/1/24 - Miss
ALKS
Sec Filings
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- 4/15/24 - Form ARS
- ALKS's page on the SEC website